AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 102 min read$PRCT

Wood Larry L purchased $498K of PRCT (indirect holdings)

Wood Larry L (President, CEO) purchased 23,900 indirectly-held shares of PROCEPT BioRobotics Corp (PRCT) at $20.85 ($0.50M total) on 2026-08-07.

Original reporting
SEC EDGAR · Wood Larry L
Published Aug 10, 2026, 10:07 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 10, 2026, 10:08 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$PRCT
Bullish
medium confidence
Mentioned
$PRCT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PRCTBullishLow
01

Why it matters

This provides a new, dated insider purchase detail (23,900 shares at $20.85) but does not include any new clinical, regulatory, financial, or strategic information that would change valuation assumptions.

02

Market read

Traders may view the insider purchase as a modest bullish sentiment input, but it is unlikely to be a standalone driver of price without accompanying fundamentals.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it also does not clarify the source of the indirect position or whether it is part of a broader compensation or trust structure.

Relevance 5/10Novelty 4/10Timing: filed 2026-08-10, transaction dated 2026-08-07

Background

The article is a SEC Form 4 insider transaction disclosure for Procept BioRobotics (PRCT).

Company-level read

Ticker impact

$PRCTBullishMedium confidence
Context

Procept BioRobotics CEO Larry L Wood filed a Form 4 for an indirect open-market purchase of 23,900 shares at $20.85 on 2026-08-07.

Expected impact

Likely limited near-term impact; may modestly support sentiment if traders treat insider buying as bullish.

Evidence & confidence

Form 4s are primary disclosures, but this is an indirect holding and the text provides no new company-specific operational or financial information.

Market effects

Sector

No direct sector read-through; this is a single-company insider transaction.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be driven by diversification, tax planning, or pre-existing arrangements, and indirect holdings may not reflect immediate conviction.

Key entities

  • issuer
    PROCEPT BioRobotics Corp

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Wood Larry L

    President and CEO; reported an indirect open-market purchase.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PRCT insider trading history →

Related articles

AUG 11
$PRCTMed

PRCT Investor Announcement: PROCEPT BioRobotics Sued on behalf of Investors to Recover Losses after Artificially Inflated Revenue Leads to 18% Stock Drop

Bleichmar Fonti & Auld LLP says a securities fraud class action has been filed against PROCEPT BioRobotics (NASDAQ:PRCT) and executives after an alleged discount program that incentivized bulk handpiece orders, potentially inflating revenue. The suit cites an 18% stock drop in Feb 2026 and earlier declines tied to Q2 2025, Q3 2025, and Q4 2025 results.

prnewswire.com3 min
AUG 6
Med

PROCEPT BioRobotics Corporation Q2 2026 Earnings Call Summary

Procept BioRobotics reported Q2 2026 revenue up 19% year over year to $94.5 million, citing HYDROS system demand and record ASPs, while U.S. procedures grew 21% but missed expectations due to softness in legacy AQUABEAM accounts. Full-year 2026 revenue guidance remains $390 million to $410 million; U.S. procedures guidance lowered to 54,000–56,000. Management expects positive adjusted EBITDA in Q4 2026 and ongoing HYDROS replacement cycle through 2027.

yahoo.com6 min
JUL 30
$PRCTMedAI 8/10

Processa Pharmaceuticals Acquires Vidya Therapeutics and Secures $200 Million Financing to Advance BTK Inhibitor Pipeline

The acquisition transforms Processa's pipeline with the addition of clinical-stage BTK inhibitor VT-7208, while a concurrent $200 million private placement is expected to fund development into 2029. Key Investor Takeaways Processa Pharmaceuticals (NASDAQ:PRCT) acquired Vidya Therapeutics, adding clinical-stage BTK inhibitor VT-7208 to its pipeline. The company simultaneously secured a private placement expected to raise approximately $200 million to fund multiple Phase 2 clinical programs.

yahoo.com6 min
JUN 30
$PRCTMed

Evercore Initiates PROCEPT BioRobotics (PRCT) At “Outperform,” Cites Aquablation Growth Potential

PROCEPT BioRobotics (NASDAQ:PRCT) reported progress in its WATER IV prostate cancer program: enrollment completed for WATER IV RP (280 patients; Aquablation vs radical prostatectomy) with primary results expected at the AUA meeting in spring 2027, and FDA IDE approval for WATER IV AS (up to 333 patients; Aquablation vs active surveillance). Evercore ISI initiated coverage with an “Outperform” rating and $30 price target.

finance.yahoo.com4 min